Chronic Constipation Linked to Gut-Brain Axis, Study Suggests
Chronic constipation affects up to 15 percent of the global population, significantly impacting quality of life. A recent study published in Frontiers in Immunology sheds light on the complex interplay between chronic constipation and the gut-brain axis, proposing that disruptions in gut microbiota may play a crucial role in this condition. The study categorizes constipation into subtypes, with slow-transit constipation (STC) being a notable example. STC is characterized by reduced gastrointestinal motility, potentially linked to abnormalities in the enteric nervous system (ENS), often referred to as the body's 'second brain.'
The researchers introduce a framework termed the "Trigger–Gateway–Hub–Effector model," which aims to integrate existing evidence from human, animal, and in vitro studies. In this model, gut dysbiosis serves as the "Trigger," where shifts in microbial populations—possibly due to diet or lifestyle—lead to the production of various metabolites. These metabolites can influence the intestinal epithelial barriers, which are critical for nutrient absorption and preventing harmful substances from entering the bloodstream.
Current evidence suggests an association between changes in gut microbiota and constipation, although the overall evidence remains moderate and primarily stems from observational studies rather than direct mechanistic data. Some beneficial microbial compounds, such as short-chain fatty acids produced from dietary fiber fermentation, are highlighted for their positive effects on gut health.
The study further explains that a compromised intestinal barrier may allow microbial metabolites to induce inflammation and disrupt neuromuscular functions, potentially exacerbating conditions like irritable bowel syndrome (IBS). The "Gateway" in the framework refers to these intestinal membranes, which, when weakened, may facilitate downstream immune and ENS interactions that affect motility.
The "Hub" represents the microenvironment surrounding the ENS, where various signals from neurons, immune cells, and microbes converge. Disruptions in this communication can impair the muscularis externa, the layer responsible for peristalsis, which is essential for bowel movements.
Finally, the "Effector" denotes the ENS itself, where signals from gut microbiota, epithelial cells, and immune responses converge to influence gastrointestinal motility. The study suggests that addressing dysbiosis through probiotics or prebiotics, as well as targeting immune function and protecting neuronal health, could offer new therapeutic avenues for managing chronic constipation. These approaches may be used in conjunction with traditional laxatives to enhance treatment efficacy.
This research emphasizes the need for a multifaceted approach to understanding and treating chronic constipation, highlighting the importance of gut health in overall metabolic function. The findings underscore the potential for innovative therapies that focus on restoring balance within the gut microbiota and improving neuromuscular function.




